Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy

Ghalandari, Behafarid; Asadollahi, Kazem; Shakeri‐Zadeh, Ali; Komeili, Ali; Riazi, Gholamhossein; Kamrava, Seyed Kamran; Attaran, Neda

doi:10.1016/j.jphotobiol.2019.01.012

Cited by 33 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, an ideal nanoparticle used in CNS drug delivery should efficiently cross the blood-brain barrier (BBB) and be specific enough to reach the targeted sites; the ideal nanoparticle would also have suitable physiochemical features, good biocompatibility and efficient scale-up for production. To date, several tau-targeted nanomaterials have been used to deliver drugs for the treatment of AD: Behafarid et al prepared folic acid-functionalized gold nanoparticles (FA-AuNPs) and Gold-Fe 3 O 4 core-shell nanoparticles (AuFeNPs), which exhibited binding affinity for both tubulin and tau [14]; Shweta et al [15] found that protein-capped metal nanoparticles could inhibit tau aggregation in Alzheimer's disease. However, problems with some of these inorganic nanomaterials still exist, such as difficult biodegradation in vivo and intolerable adverse side effects.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease

Gao¹,

Chu

Gong³

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

Background: Although many therapeutic strategies for Alzheimer's disease (AD) have been explored, these strategies are seldom used in the clinic. Therefore, AD therapeutic research is still urgently needed. One major challenge in the field of nanotherapeutics is to increase the selective delivery of drugs to a targeted location. Herein, we devised and tested a strategy for delivery of nanoparticles to neurons to inhibit tau aggregation by directly targeting p-tau. Results: Curcumin (CUR) is loaded onto red blood cell (RBC) membrane-coated PLGA particles bearing T807 molecules attached to the RBC membrane surface (T807/RPCNP). With the advantage of the suitable physicochemical properties of the PLGA nanoparticles and the unique biological functions of the RBC membrane, the RPCNP are stabilized and promote sustained CUR release, which provided improved biocompatibility and resulted in long-term presence in the circulation. Under the synergistic effects of T807, T807/RPCNP can not only effectively penetrate the blood-brain barrier (BBB), but they also possess high binding affinity to hyperphosphorylated tau in nerve cells where they inhibit multiple key pathways in tau-associated AD pathogenesis. When CUR was encapsulated, our data also demonstrated that CUR-loaded T807/RPCNP NPs can relieve AD symptoms by reducing p-tau levels and suppressing neuronal-like cells death both in vitro and in vivo. The memory impairment observed in an AD mouse model is significantly improved following systemic administration of CUR-loaded T807/RPCNP NPs. Conclusion: Intravenous neuronal tau-targeted T807-modified novel biomimetic nanosystems are a promising clinical candidate for the treatment of AD.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease

Gao¹,

Chu

Gong³

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…First, 300 μl of 1% chloroauric acid (HAuCl4•3H2O) (Sigma-Aldrich, Oakville, ON, Canada) was added to 30 mL of NP transport is heavily dependent on the MT network. Hence, the MT network is a good target for modulating NP dynamics to improve therapeutics [27,28]. If we were to successfully integrate both DTX and NPs into any NP-driven therapeutic approach, the following questions need to be answered: (a) Does NP size matter?…”

Section: Gnp Preparation and Modificationmentioning

confidence: 99%

“…To answer the above questions, we chose GNPs as our model NP system due to their biocompatibility and ease of tailoring size and surface functionalization [14,[17][18][19]. Evidence of their promise in therapeutic and imaging applications has been mentioned previously [28,29].…”

Section: Introductionmentioning

confidence: 99%

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) have shown promise in both radiotherapy and chemotherapy. NPs are mainly transported along cellular microtubules (MTs). Docetaxel (DTX) is a commonly used chemotherapeutic drug that can manipulate the cellular MT network to maximize its clinical benefit. However, the effect of DTX on NP behaviour has not yet been fully elucidated. We used gold NPs of diameters 15 and 50 nm at a concentration of 0.2 nM to investigate the size dependence of NP behaviour. Meanwhile, DTX concentrations of 0, 10 and 50 nM were used to uphold clinical relevance. Our study reveals that a concentration of 50 nM DTX increased NP uptake by ~50% and their retention by ~90% compared to cells treated with 0 and 10 nM DTX. Smaller NPs had a 20-fold higher uptake in cells treated with 50 nM DTX vs. 0 and 10 nM DTX. With the treatment of 50 nm DTX, the cells became more spherical in shape, and NPs were redistributed closer to the nucleus. A significant increase in NP uptake and retention along with their intracellular distribution closer to the nucleus with 50 nM DTX could be exploited to target a higher dose to the most important target, the nucleus in both radiotherapy and chemotherapy.

show abstract

“…Because of unique characteristics, functional materials with photothermal conversion properties are favored in biological applications, and many biomaterials have been developed and applied to the PTT‐based cancer treatment filed. [ 11–16 ]…”

Section: Introductionmentioning

confidence: 99%

Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy

2021

View full text Add to dashboard Cite

Phototherapy such as photothermal therapy and photodynamic therapy in cancer treatment has been developed quickly over the past few years for its noninvasive nature and high efficiency. However, there are still many drawbacks in phototherapy that prevent it from clinical applications. Thus, scientists have designed different systems to overcome the issues associated with phototherapy, including enhancing the targeting ability of phototherapy, low‐temperature photothermal therapy, replacing near‐infrared light with other excitation sources, and so on. This article discusses the problems and shortcomings encountered in the development of phototherapy and highlights possible solutions to address them so that phototherapy may become a useful cancer treatment approach in clinical practice. This article aims to give a brief summary about current research advancements in phototherapy research and provides a quick guideline toward future developments in the field.

show abstract

Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy

Cited by 33 publications

References 30 publications

RETRACTED ARTICLE: Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease

RETRACTED ARTICLE: Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy

Contact Info

Product

Resources

About